With $4M in New Funding, Aviva Upgrades ChIP-on-Chip Service, Plans Expansion | GenomeWeb
Aviva Systems Biology, a privately held San Diego company, last week announced that it has raised $4 million to upgrade its flagship chromatin immunoprecipitation-on-chip service offering, move to a larger facility, and lay the groundwork for a major staff expansion this year.
 
Jeff Falk, director of technology and business applications at Aviva, told BioArray News via e-mail this week that the new funding round, secured from existing investors, closed in December. He declined to name the investors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.